1. אתמול קיבלה שוב המלצה עם יעד של $22 אתמול קיבלה שוב המלצה עם יעד של $22 VBL Therapeutics' (VBLT) ASCO Data Emphasizes VB-111's Potential in Multiple Tumors - Roth Capital June 6, 2016 2:16 PM EDT Roth Capital affirms VBL Therapeutics (Nasdaq: VBLT) at Buy with a price target of $22 following presentation of updated clinical results from a Phase 1/2 trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer. Analyst Joseph Pantginis commented today, We believe the updates at ASCO underscore VB-111's potential in multiple tumor types known to be driven by angiogenesis by also adding an immunotherapy component. The results from the Phase I/II study in Ptresistant ovarian cancer complement nicely to those seen in rGBM. Next steps for the program in the indication include an end of Phase II meeting with the FDA, that could occur by year's end. For an analyst ratings summary and ratings history on Vascular Biogenics Ltd click here. For more ratings news on Vascular Biogenics Ltd click here Cherries | 07.06.16 (ל"ת)
אחרי זינוק של 72%: וסקולר ביוג'ניקס מודיעה על גיוס של 24 מיליון דולר
1 תגובות לכתיבת תגובה